Your Cart Is Empty!
Find out which emerging markets offer the best investment prospects for orphan drug manufacturers.
Based on interviews with eight senior executives and two specialist market access consultants, the report explores more than 35 emerging markets, and gives you a ranked list of the 15 most promising targets.
You'll understand emerging markets’ unique dynamics, hear about local stakeholders who help shape the market, and learn how to build the critical mass your product needs to win broad reimbursement at a fair price.
Actionable information for orphan drug manufacturers
Understand emerging markets: Breakdowns of the strengths, weaknesses, opportunities, and threats (SWOT analysis) paint a clear picture of the market access climate four major regions.
Learn the facts on the ground: Charts and tables show you at-a-glance the unique market access barriers and opportunities you’re likely to encounter in 35 emerging markets.
Pinpoint the best opportunities: A ranked list of the 15 most promising emerging markets shows you which countries offer the pricing and reimbursement climates for manufacturers.
Get expert insight: Benefit from the verbatim comments of orphan-drugs experts, including top industry executives and experienced advisors with hands-on experience in emerging markets.
Find out what works: Get in-depth analysis of successful real-world strategies, including special access pathways for orphan drugs (pre-registration coverage, named patient programmes, etc.).
Answering Key Questions
Unfamiliar territory: The systems and standards that determine access for orphan drugs in advanced markets don’t apply in emerging markets. So what exactly are the ground rules?
Learn the local laws: Every emerging market has a different legal framework for orphan drugs. Find out how to navigate this ever-changing environment successfully.
Take a hands-on approach: In emerging markets, market-shaping may extend to helping locals close gaps in the health system. What kind of support should you be prepared to offer?
Don’t overstep: How do you ensure that your market-shaping activities align with local regulations, compliance protocols, and resource constraints?
Education is key: How does helping patients, payers and physicians understand rare disease treatment influence the conversation around market access?
Know who your friends are: Most emerging markets have friendly non-payer stakeholders with an interest in helping you broaden access to orphan drugs. Who are your most likely allies?
The report is based on structured interviews with 10 subject matter experts: eight senior market access executives from leading orphan drug manufacturers, and two specialist market access consultants.
Sam Pearce, VP & General Manager EMEA Emerging Markets, Celgene
Ad Rietveld, Partner, RJW & Partners
Charles Rowlands, Managing Director, Parioforma Consulting
Helen Stoop, Regional Market Access Lead - Central Eastern Europe, Middle East and Africa (CEEMEA), Shire Pharmaceuticals.
Brazil Market Access Director, Rare Diseases-Focused Biopharmaceutical Company
Colombia Director, Top 10 Biopharmaceutical Company
Latin America Market Access Director, Leading Orphan Drug Company
International Marketing Director, Europe-based orphan drug manufacturer
Market Access Director, Rare Cancers-focused Biopharmaceutical Company
Orphan Disease Area Lead, Top 10 global pharmaceutical company
All respondents are responsible for their respective regions, or have special expertise in the countries surveyed, having led value dossier submissions and/or payer negotiations.
Interviews were conducted in April and May of 2016.
Table of Contents
3.1.SWOT Analysis: Market Access for Orphan Drugs in Emerging Markets
5.Market shaping for orphan medicines in emerging markets
5.1.Access to orphan drugs in emerging markets is inconsistent
5.2.On paper, access is better than might be expected
5.3.In emerging markets, market shaping has a broader definition
5.4.Disease guidelines can give local experts a voice
5.5.Emerging-market physicians and patients are eager to engage
6.Market access and pricing for orphan medicines in emerging markets
6.1.Registries, not risk shares, can address payer uncertainty
6.2.Conditional Coverage Has Limited Scope in Emerging Markets
6.3.Named Patient Programmes are a Time-Limited Solution
6.4.Orphan Drugs’ High-Price, Low-Budget Impact Business Model is Problematic
6.4.Market Segmentation is a Critical Success Factor
7.Middle East & Africa
7.1.SWOT Analysis: Middle East & Africa
7.2.Some Middle Eastern populations have unique rare disease characteristics
7.3.Wealthy populations and first-class infrastructure, but pricing is a challenge
7.4.Pricing and reimbursement barriers in the Middle East & Africa
7.4.Market access is highly specific to the local context
8.1.SWOT Analysis: Latin America
8.2.Niche reimbursement, and court injunctions, drive the opportunity in Latin America
8.3.Some Latin American payers cannot meet their policy commitments
9.Eastern Europe & Central Asia
9.1.SWOT Analysis: Central & Eastern European Emerging Markets
9.2.Russia is the largest market, but is challenging for foreign companies
9.3.European Union and Periphery: Transitioning from Price Markets to HTA markets
10.Asia and the Pacific Rim
10.1.SWOT Analysis: Asia and the Pacific Rim
10.2.Rare Diseases Struggle to Gain Acceptance in China and India
10.3.Mid-Sized Asian Markets Offer Small Opportunities for Orphan Drugs
12.About the author
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.